Claims-defined hepatic steatosis compatible with MASLD and reproductive outcomes after the first observed embryo transfer: a Korean nationwide cohort study
6 affiliations
- 1Medical Big Data Research Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea
- 2Department of Physiology, School of Medicine, CHA University, Pocheon-si, Republic of Korea
- 3Center for Translational Medicine, Medical Center Research Institute, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea
- 4Digestive Disease Center, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Republic of Korea
- 5Digestive Disease Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea
- 6Department of Clinical Pharmacology & Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea
Abstract
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly prevalent among women of reproductive age; however, its association with reproductive outcomes after in vitro fertilization (IVF) remains insufficiently characterized in population-level data. We evaluated pre-index claims-defined hepatic steatosis compatible with MASLD as the primary exposure of interest in relation to first claims-identified pregnancy and time to first claims-identified live birth after the first observed embryo transfer (ET). Inflammatory bowel disease, irritable bowel syndrome, and autoimmune hepatobiliary disease were included as gastrointestinal and hepatic comparators.
Methods: We conducted a retrospective cohort study using Korean National Health Insurance Service claims data from 2017 to 2024. Among 601,664 women with an infertility diagnosis (ICD-10 N97), 122,134 underwent a first observed ET between 2019 and 2023 after predefined exclusions. Exposures were ascertained from pre-index claims using disease-specific ascertainment windows. The co-primary outcomes were first claims-identified pregnancy and time to first claims-identified live birth after the index ET. Claims-defined pregnancy loss was a secondary outcome among women with a first claims-identified pregnancy. Associations were analyzed using inverse probability of treatment weighting (IPTW)-adjusted Cox and logistic regression models, with false discovery rate (FDR) correction and E-value analyses.
Results: Among 122,134 women (mean age, 36.4 ± 4.2 years), 82.1% had a first claims-identified pregnancy and 62.7% had a claims-identified live birth during follow-up. After IPTW adjustment, claims-defined hepatic steatosis compatible with MASLD was associated with a modestly lower hazard of first claims-identified pregnancy (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.88–0.98; FDR q = 0.049) and first live birth during follow-up (HR 0.88; 95% CI 0.82–0.94; FDR q = 0.0006). It was not associated with claims-defined pregnancy loss among women with a first claims-identified pregnancy.
Conclusions: Pre-index claims-defined hepatic steatosis compatible with MASLD was associated with modestly lower hazards of first claims-identified pregnancy and first live birth during follow-up. Because body mass index, ovarian-reserve markers, clearly separated ovarian phenotypes, male-factor information, and cycle-level characteristics were unavailable, MASLD-compatible hepatic steatosis may represent a broader metabolic–reproductive phenotype rather than an independent hepatic effect. Given the modest E-values, these findings are hypothesis-generating and should not be interpreted causally or used alone to guide individual IVF counseling or treatment decisions.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-05231-4.
Related
- Fatty liver index-defined hepatic steatosis and impaired fasting glucose differentially associate with incident diabetes and cardiovascular events in older adults: a nationwide cohort study
- Institutional Perspectives on Assisted Reproductive Technology Using Third‐Party Gametes in Japan: A Nationwide Survey of Assisted Reproductive Technology Facilities
- Long-term outcomes of ultrasound-detected hepatic steatosis in primary care: a record linkage study
- Silymarin-Based Therapies in Chronic Liver Disease: A Systematic Review of Biochemical, Cardiometabolic, Steatosis, and Fibrosis-Related Outcomes
- Rural-urban inequalities and determinants of period poverty among women of reproductive age in Nigeria: evidence from a nationwide study.
BibTeX
@article{you2026claimsdefined,
title = {{Claims-defined hepatic steatosis compatible with MASLD and reproductive outcomes after the first observed embryo transfer: a Korean nationwide cohort study}},
author = {Seung-Hun You and Dong Hyeon Lee and Ah Young Lee and Kwanjoo Lee and Wonsuk Shin and Jun-young Seo},
journal = {BMC Gastroenterology},
year = {2026},
month = aug,
doi = {10.1186/s12876-026-05231-4},
url = {https://doi.org/10.1186/s12876-026-05231-4},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Claims-defined hepatic steatosis compatible with MASLD and reproductive outcomes after the first observed embryo transfer: a Korean nationwide cohort study
AU - Seung-Hun You
AU - Dong Hyeon Lee
AU - Ah Young Lee
AU - Kwanjoo Lee
AU - Wonsuk Shin
AU - Jun-young Seo
PY - 2026
DA - 2026/08/15
JO - BMC Gastroenterology
DO - 10.1186/s12876-026-05231-4
UR - https://doi.org/10.1186/s12876-026-05231-4
AB - Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly prevalent among women of reproductive age; however, its association with reproductive outcomes after in vitro fertilization (IVF) remains insufficiently characterized in population-level data. We evaluated pre-index claims-defined hepatic steatosis compatible with MASLD as the primary exposure of interest in relation to first claims-identified pregnancy and time to first claims-identified live birth after the first observed embryo transfer (ET). Inflammatory bowel disease, irritable bowel syndrome, and autoimmune hepatobiliary disease were included as gastrointestinal and hepatic comparators. Methods: We conducted a retrospective cohort study using Korean National Health Insurance Service claims data from 2017 to 2024. Among 601,664 women with an infertility diagnosis (ICD-10 N97), 122,134 underwent a first observed ET between 2019 and 2023 after predefined exclusions. Exposures were ascertained from pre-index claims using disease-specific ascertainment windows. The co-primary outcomes were first claims-identified pregnancy and time to first claims-identified live birth after the index ET. Claims-defined pregnancy loss was a secondary outcome among women with a first claims-identified pregnancy. Associations were analyzed using inverse probability of treatment weighting (IPTW)-adjusted Cox and logistic regression models, with false discovery rate (FDR) correction and E-value analyses. Results: Among 122,134 women (mean age, 36.4 ± 4.2 years), 82.1% had a first claims-identified pregnancy and 62.7% had a claims-identified live birth during follow-up. After IPTW adjustment, claims-defined hepatic steatosis compatible with MASLD was associated with a modestly lower hazard of first claims-identified pregnancy (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.88–0.98; FDR q = 0.049) and first live birth during follow-up (HR 0.88; 95% CI 0.82–0.94; FDR q = 0.0006). It was not associated with claims-defined pregnancy loss among women with a first claims-identified pregnancy. Conclusions: Pre-index claims-defined hepatic steatosis compatible with MASLD was associated with modestly lower hazards of first claims-identified pregnancy and first live birth during follow-up. Because body mass index, ovarian-reserve markers, clearly separated ovarian phenotypes, male-factor information, and cycle-level characteristics were unavailable, MASLD-compatible hepatic steatosis may represent a broader metabolic–reproductive phenotype rather than an independent hepatic effect. Given the modest E-values, these findings are hypothesis-generating and should not be interpreted causally or used alone to guide individual IVF counseling or treatment decisions. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12876-026-05231-4.
SN - 1471-230X
ER -